NHS Dudley Health Economy Medicines Formulary
Home > 3 Respiratory system > 3.11 Antifibrotics > Idiopathic pulmonary fibrosis - pirfenidone - NICE TAG TA282

Idiopathic pulmonary fibrosis - pirfenidone - NICE TAG TA282

1.1 Pirfenidone is recommended as an option for treating idiopathic pulmonary fibrosis only if:

  • the person has a forced vital capacity (FVC) between 50% and 80% predicted and

  • the manufacturer provides pirfenidone with the discount agreed in the patient access scheme.

1.2 Treatment with pirfenidone that is recommended according to 1.1 should be discontinued if there is evidence of disease progression (a decline in per cent predicted FVC of 10% or more within any 12 month period).

1.3 People currently receiving pirfenidone that is not recommended according to 1.1 should have the option to continue treatment until they and their clinician consider it appropriate to stop.

http://www.nice.org.uk/guidance/TA282

Site by Devopa
© Copyright 2020 NHS. All rights reserved.